Europe
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Lysogene and Sarepta Therapeutics will end a licensing agreement after failed discussions of transferring global commercial supply rights for the LYS-SAF302 asset back to Lysogene.
One of the big stories this week that even momentarily eclipsed COVID-19, was the landmark transplant of a genetically modified pig heart into a human male with terminal heart disease. For that and more research stories, read on.
Imcyse’s peptides work by priming cytolytic T cells to recognize and destroy those immune cells attacking the pancreas beta cells.
For a look at what’s going on with kids and COVID-19, and related stories, continue reading.
NRx is seeking $185 million in damages and claims that Relief has breached the collaboration agreement established in 2020 regarding the development of the COVID-19 drug, aviptadil.
According to the Environmental Litigation Group, P.C., approximately 37.5% of all occupational lung cancer cases are related to occupational asbestos exposure.
Sanofi will pay ABL $75 million upfront, and the latter is eligible to receive as much as $985 million down the line as development, regulatory, and commercialization milestones are met.
Bayer has transformed its pipeline by acquiring multiple cell and gene therapy companies, paving the way for life-saving and life-altering therapies for patients with different disease types.
California-based Dren Bio and Pfizer have partnered on a deal valued at more than $1 billion to discover and develop therapeutic bispecific antibodies for select oncology targets.
PRESS RELEASES